Psilocybin Feasibility Trial for Treatment-Resistant Depression
Key Takeaways
- Adults with treatment-resistant major depressive disorder treated in England’s National Health Service had larger depressive-symptom reductions over 6 weeks after a single 25-mg psilocybin dose with structured psychological support than after placebo.
- Feasibility signals were strong, with 83% eligibility, 80% randomization, 100% dosing attendance, and 98% completion of Montgomery–Åsberg Depression Rating Scale assessments through week 6.
- Categorical improvement also favored psilocybin, with week-3 MADRS response of 43% versus 3% and week-3 remission of 40% versus 3%; psilocybin response increased to 50% by week 6.
- In the psilocybin cohort, no treatment-related serious adverse events were reported, and nonserious adverse events were more numerous with psilocybin than with placebo.
- Functional unblinding, expectancy effects, limited ethnic representation, and the feasibility design temper interpretation of the short-term signal.
Rucker and colleagues conducted the Nature Medicine randomized trial of psilocybin-assisted therapy for treatment-resistant major depressive disorder, a randomized, double-blind, placebo-controlled Phase 2 feasibility study at one National Health Service site in England. Investigators enrolled 60 adults aged 25-80 years with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition major depressive disorder and treatment-resistant depression, defined by inadequate response to at least two antidepressant trials or one antidepressant plus one psychotherapy trial; most had a chronic course of illness and moderate treatment resistance. Participants were randomized 1:1 to a single oral 25-mg dose of synthetic psilocybin (COMP360) or matching placebo, then underwent a 1-8-week preparation period that included withdrawal of relevant antidepressant, antipsychotic, or mood-stabilizing medications. Dosing took place in a 6-hour monitored session with a therapist and chaperone, followed by integration therapy. Primary endpoints focused on recruitment, retention, and estimation of Montgomery–Åsberg Depression Rating Scale (MADRS) variance, and secondary outcomes included changes in MADRS, the Quick Inventory of Depressive Symptomatology (QIDS-SR-16), and other mental health and functioning measures assessed at baseline and weeks 1, 3, and 6.
Depressive symptoms separated quickly between groups, with adjusted between-group MADRS differences of -10.41 points at week 3 (Cohen’s d = -1.70) and -12.92 points at week 6 (Cohen’s d = -2.11). Response and remission outcomes, along with self-reported depression, generalized anxiety, and functional impairment, moved in the same direction. Because the trial did not undertake formal hypothesis testing, investigators treated these findings as preliminary effect estimates. Symptom reductions were rapid and sustained through the 6-week randomized phase.
In the psilocybin cohort, no treatment-related serious adverse events were reported, while 164 nonserious adverse events occurred in the psilocybin arm versus 123 with placebo; most were mild and resolved during the study period. Recruitment, dosing attendance, and follow-up completion remained strong enough to support further study of this care pathway within England’s National Health Service. The observed safety profile was marked by more frequent nonserious events with psilocybin, and no treatment-related serious adverse events were reported in the psilocybin cohort.
Interpretation remains limited by the feasibility design and the England public-system setting. Functional unblinding related to the subjective psychedelic experience, along with possible expectancy effects, may have contributed to between-group differences, and limited ethnic representation narrows the reported scope. For North American readers, the main relevance is that the pathway was tested inside a large public mental health system rather than as a direct model for U.S. practice. The findings reflect delivery within England’s National Health Service and do not by themselves show how the same workflow would perform in other care systems.
Rucker and colleagues concluded that a single-dose psilocybin-assisted approach could be delivered within National Health Service care in England and was associated with short-term symptom improvement in treatment-resistant major depressive disorder. They also stated that larger and longer-term trials are still needed to confirm magnitude and durability, assess functional outcomes and cost-effectiveness, and determine whether benefits persist beyond the 6-week randomized phase.
Clinician Questions
Which patients with treatment-resistant major depressive disorder were included in the NHS psilocybin trial?
Investigators enrolled adults aged 25-80 years with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition major depressive disorder who had not responded adequately to at least two antidepressant trials or to one antidepressant plus one psychotherapy trial. Participants had experienced significant depression for a mean of 20 years, most were described as having moderate treatment resistance and a chronic course of illness, and all were treated at a single National Health Service site in England, which limits how broadly the findings extend.
How was psilocybin-assisted therapy delivered in the NHS treatment-resistant depression pathway?
The intervention was delivered as a structured care pathway rather than capsule administration alone. Participants were assigned to a single oral 25-mg dose of synthetic psilocybin or matching placebo after 1-8 weeks of psychological preparation, relevant antidepressant, antipsychotic, or mood-stabilizing medications were withdrawn during preparation, dosing occurred during a 6-hour monitored session with a therapist and chaperone, and integration therapy followed.
Why were the psilocybin results described as preliminary in treatment-resistant depression?
The findings were framed as preliminary because the trial was a Phase 2 feasibility study whose primary endpoints centered on recruitment, retention, and estimation of MADRS variance rather than definitive efficacy testing. Investigators did not undertake formal hypothesis testing for clinical outcomes, so the depression results were presented as preliminary effect estimates rather than confirmatory evidence.
What remained unanswered after 6 weeks of psilocybin treatment for treatment-resistant depression?
The randomized phase covered 6 weeks, so durability beyond that period was not established in adults with treatment-resistant major depressive disorder treated in England’s National Health Service. Investigators said larger and longer-term trials are needed to confirm magnitude and durability, evaluate functional outcomes and cost-effectiveness, and account for the possibility that functional unblinding and expectancy effects contributed to between-group differences.